<DOC>
	<DOCNO>NCT02533570</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability brentuximab vedotin adult active systemic lupus erythematosus ( SLE ) .</brief_summary>
	<brief_title>Dose Ranging Study Brentuximab Vedotin Adults With Lupus</brief_title>
	<detailed_description>Systemic lupus erythematosus ( SLE ) chronic , multisystem , disable autoimmune condition , predominantly affect woman childbearing year . Treatment option SLE remain relatively limited . Regardless specific therapy chosen , majority patient continue require long term immunomodulatory cytotoxic therapy , result long-term morbidity mortality . Brentuximab vedotin antibody-drug conjugate ( ADC ) consist : 1 ) chimeric immunoglobulin ( Ig ) G1 antibody cAC10 , specific human CD30 , 2 ) microtubule disrupt agent monomethyl auristatin E ( MMAE ) , 3 ) protease-cleavable linker covalently attach MMAE cAC10 . Since CD30 and/or CD30-expressing immune cell may play significant key role pathogenesis SLE , brentuximab vedotin may efficacious therapy . This study intend explore potential brentuximab vedotin therapy SLE .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adults ≥ 18 year Diagnosis SLE least 6 month prior screen Active SLE indicate SLE Disease Activity Index ( SLEDAI ) ≥ 4 screen Must fail treatment SLE trial least 3 month The subject serious health condition , , opinion Investigator , would place subject undue risk study Subject recent serious ongoing infection , risk serious infection Subject history new recurrent malignancy within past 5 year The subject pregnant and/or breastfeed The subject fulfill diagnostic criterion another rheumatic ( overlap ) disease may confound clinical assessment study The subject urgent , severe SLE disease activity , , opinion Investigator , warrant immediate immunosuppressive therapy would appropriate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Lupus</keyword>
</DOC>